Skip to main content

Table 3 Factors associated with severe adverse events in women initiating NVP-based antiretroviral therapy.

From: Incidence and risk factors of severe adverse events with nevirapine-based antiretroviral therapy in HIV-infected women. MTCT-Plus program, Abidjan, Côte d'Ivoire

 

All severe adverse events (N = 88)†

Severe hepatotoxicity(N = 10)

ZDV-related severe averse events (N = 71)

 

HR

95% CI

p

HR

95% CI

p

HR

95% CI

p

Age (years)

         

   ≥30 (n = 137)

1.03

0.67-1.59

0.90

1.37

0.37-5.06

0.64

0.92

0.57-1.49

0.74

   <30 (n = 153)

1.00

-

-

1.00

-

-

1.00

-

-

Body mass index (Kg/m 2 )

         

   <18 (n = 40)

1.08

0.53-2.20

0.05

   

1.12

0.52-2.42

0.78

   ≥18 (n = 160)

1.00

-

-

   

1.00

-

-

CD4+ count/mm 3

         

   >250 (n = 88)

0.68

0.41-1.12

0.14

1.75

0.48-6.39

0.40

0.64

0.36-1.14

0.13

   ≤250 (n = 202)

1.00

-

-

1.00

-

-

1.00

-

-

WHO staging

         

   Stage 3 or 4 (n = 130)

1.00

0.63-1.58

0.99

1.31

0.36-4.74

0.68

1.07

0.65-1.79

0.77

   Stage 1 or 2 (n = 160)

1.00

-

-

1.00

-

-

1.00

-

-

ALT (IU/L)

         

   ≥31(n = 50)

1.58

0.89-2.78

0.12

7.09

1.59-31.62

0.01

1.10

0.57-2.15

0.78

   <31(n = 240)

1.00

-

-

1.00

-

-

1.00

-

-

Neutrophil level (/mm 3 )

         

   <1500 (n = 28)

1.51

0.76-2.98

0.24

   

2.20

1.09-4.43

0.03

   ≥1500 (n = 262)

1.00

-

-

   

1.00

-

-

Hemoglobin level (g/dL)

         

   ≤9.8 (n = 150)

1.15

0.73-1.82

0.56

0.66

0.16-2.79

0.57

1.35

0.81-2.23

0.25

   >9.8 (n = 140)

1.00

-

-

1.00

-

-

1.00

-

-

Status of pregnancy

         

   Pregnant (n = 125)

0.98

0.60-1.64

0.98

1.22

0.22-6.62

0.82

1.11

0.65-1.91

0.70

   Non pregnant (n = 165)

1.00

-

-

1.00

-

-

1.00

-

-

  1. Multivariable Cox regression analyses. MTCT-Plus program, Abidjan, Côte d'Ivoire (2003-2006).
  2. HAART: Highly active antiretroviral therapy; WHO: World Health Organization; IQR: interquartile range; NVP: nevirapine; ALT: alanine aminotransferase; OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval, † If a woman had multiple severe adverse event